| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/14/2003 | US6506884 Variant of vascular endothelial growth factor |
| 01/14/2003 | US6506883 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| 01/14/2003 | US6506881 Specific for human milk fat globule; complementarity determining region derived from variable domains of mouse monoclonal antibody |
| 01/14/2003 | US6506880 For inhibiting atherosclerosis |
| 01/14/2003 | US6506879 Endotoxin-free; genetically expressed in bacteria; atherosclerosis and cardiovascular disorder treatment |
| 01/14/2003 | US6506878 HMTF81 human 7-transmembrane receptor |
| 01/14/2003 | US6506877 Ob receptor |
| 01/14/2003 | US6506875 Diagnostic epitopes |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506786 HIV protease inhibitors based on amino acid derivatives |
| 01/14/2003 | US6506774 The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. |
| 01/14/2003 | US6506761 Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
| 01/14/2003 | US6506760 Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
| 01/14/2003 | US6506759 Retroviral protease inhibitors |
| 01/14/2003 | US6506754 Compounds as anticoagulants |
| 01/14/2003 | US6506735 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
| 01/14/2003 | US6506734 20(S) camptothecin glycoconjugates |
| 01/14/2003 | US6506732 Utilization of whey protein hydrolysate as the active ingredient in skin care composition |
| 01/14/2003 | US6506731 Elastin peptide analogs and methods of using same |
| 01/14/2003 | US6506730 Nasal transmucosal delivery of peptide conjugated with biocompatible polymers |
| 01/14/2003 | US6506729 Methods and compositions for the treatment and prevention of Parkinson's disease |
| 01/14/2003 | US6506728 Methods using a novel neurotrophic factor, NT-4 |
| 01/14/2003 | US6506727 Contacting said nerve with purified platelet-derived growth factor and a second purified growth factor selected from the group consisting of insulin-like growth factor-I and acidic fibroblast growth factor |
| 01/14/2003 | US6506726 Purification of an Echinocandin-type compound by adsorption onto a hydrophobic, reversed phase chromatographic media and eluting with a continuous nearly linear gradient of increasing acetic acid |
| 01/14/2003 | US6506725 Ultra pure hemoglobin solutions and blood-substitutes |
| 01/14/2003 | US6506724 Exendins are peptides that were first isolated from the salivary secretions of the Gila-monster, a lizard found in Arizona and have some sequence similarity to several members of the glucagon-like peptide |
| 01/14/2003 | US6506587 Nucleotide sequences coding enzymatic polypeptide; for use as an antitumor a gents |
| 01/14/2003 | US6506586 Nucleic acids encoding polypeptides having haloperoxidase activity |
| 01/14/2003 | US6506585 Polypeptides having haloperoxidase activity |
| 01/14/2003 | US6506582 Extended by aspartic acid at 5' end and shortened at 3' end by one to eight amino acids; nonimmunogenic; binds CD4 lymphocytes |
| 01/14/2003 | US6506580 Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening |
| 01/14/2003 | US6506578 Nucelotide encoding megakaryocytic protein tyrosine kinases |
| 01/14/2003 | US6506573 Additive formulation and method of use thereof |
| 01/14/2003 | US6506571 Human glutathione-S-transferase |
| 01/14/2003 | US6506569 Drug screening; genetic engineering |
| 01/14/2003 | US6506559 Molecular hybridization of complementary strands |
| 01/14/2003 | US6506554 Drug screening for viricides |
| 01/14/2003 | US6506550 Inducing apoptosis in cancer cells; drug screening for thiamine-depleting agents |
| 01/14/2003 | US6506549 Sodium, calcium, chloride, potassium, albumin, and sugar; plasmaphoresis |
| 01/14/2003 | US6506415 Method of inducing resistance to tumor growth |
| 01/14/2003 | US6506413 Compositions for treating animal diseases and syndromes |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506408 Implantable or insertable therapeutic agent delivery device |
| 01/14/2003 | US6506399 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 01/14/2003 | US6506398 Device for treating diabetes and methods thereof |
| 01/14/2003 | US6506389 Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/14/2003 | US6506382 Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand |
| 01/14/2003 | US6506380 Methods of preventing or treating allergies |
| 01/14/2003 | US6506377 Interferon-alpha mediated upregulation of aquaporin expression |
| 01/14/2003 | US6506365 Fibrin/fibrinogen binding conjugate |
| 01/14/2003 | US6506362 Peptides and peptide mimetics attached to labels and/or hydrophilic polymmers; treating hematological disorders, particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions |
| 01/14/2003 | CA2246758C Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii |
| 01/14/2003 | CA2229739C Recombinant conglutinin and producing method thereof |
| 01/14/2003 | CA2222303C Use of at least one no synthase inhibitor for treating sensitive skin |
| 01/14/2003 | CA2194444C Immunomodulators |
| 01/14/2003 | CA2116859C Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| 01/14/2003 | CA2115249C Phosphopeptides for the treatment of dental calculus |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/14/2003 | CA2102595C Truncated forms of the hepatocyte growth factor (hgf) receptor |
| 01/14/2003 | CA2065270C Erection-inducing methods and compositions |
| 01/14/2003 | CA2023089C Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia |
| 01/13/2003 | CA2393376A1 Assay methods |
| 01/10/2003 | CA2415709A1 Remedies for bone diseases |
| 01/09/2003 | WO2003003018A2 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/09/2003 | WO2003003017A2 Use of transcription factor nak-1 or genes regulated by transcription factor nak-1 for the diagnosis and/or therapy of inflammatory and malignant diseases |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002765A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 01/09/2003 | WO2003002745A2 The cage gene of actinobacillus actinomycetemcomitans, the protein it encodes and uses thereof |
| 01/09/2003 | WO2003002743A1 Human cervical cancer 7 proto-oncogene and protein encoded therein |
| 01/09/2003 | WO2003002739A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 01/09/2003 | WO2003002737A1 Novel human topoisomerase 2α inhibitory protein and utilization thereof |
| 01/09/2003 | WO2003002734A1 Anticomplement polypeptide from salivary glands of the tick ixodes ricinus |
| 01/09/2003 | WO2003002731A1 A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD) |
| 01/09/2003 | WO2003002729A1 A crystallised catalytic domain of matrix metalloproteinase 9 (mmp9) and the use of its three dimensional structure to design mmp9 modulators |
| 01/09/2003 | WO2003002718A2 Identification and characterization of multiple splice variants of the mu opioid receptor gene |
| 01/09/2003 | WO2003002717A2 Biological activity of ak155 |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002606A2 Nucleic acids encoding ion channels |
| 01/09/2003 | WO2003002605A2 Human secretin-like g protein-coupled receptor |
| 01/09/2003 | WO2003002602A2 Nogo and nogo receptor derived peptides for t-cell mediated neuroprotection |
| 01/09/2003 | WO2003002601A2 AFXz TRANSCRIPTION FACTOR SPLICE FORM |
| 01/09/2003 | WO2003002600A1 Use of soluble cytokeratine-1-fragments in diagnostics and therapy |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002594A1 Hypoglycaemic peptides and methods of use thereof |
| 01/09/2003 | WO2003002593A2 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 01/09/2003 | WO2003002545A1 Peptoid compounds |
| 01/09/2003 | WO2003002203A1 Peptide combination for the treatment of cancer |
| 01/09/2003 | WO2003002175A2 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | WO2003002158A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002143A1 A novel engineered superantigen for human therapy |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002139A1 Method for improving stability of protein preparation |
| 01/09/2003 | WO2003002138A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |